FireGen Medical Closes RMB 100 Million Series D Financing for Rapid Diagnostics

Сентябрь 21, 2023 Китай, Финансирование

China Beijing-based FireGen Medical has closed over RMB 100 million ($13.6 million) Series D Financing led by Jianchuang Medical Growth Fund and followed by Golden Sand Capital and Zhilai Capital, for the research and development of multiple rapid diagnostic instruments and reagents, product registration, production capacity expansion, and global commercialization.

Focusing on early screenings of hereditary tumours, FireGen Medical provides products and services covering instruments, chips, diagnostic reagents, and Internet remote diagnosis and treatment, helping promote the advanced rapid diagnosis and treatment technologies into the grassroots healthcare institutions in China.

Headquartered in Haidian District, Beijing, FireGen Medical has large-scale GMP plants and production facilities in Shandong Province and Jiangsu Province, and provides products and services to thousands of hospitals, pharmaceutical companies, scientific research institutes, and medical testing organisations around the world. Its sales network covers more than 30 countries and regions around the world, with more than one-third of sales coming from overseas.

FireGen has established long-term and stable cooperative relationships with many well-known enterprises and top hospitals, such as Fosun Pharma, Hengrui Pharmaceuticals, WuXi AppTec, Beijing GenePlus, Peking Union Medical College Hospital, and 301 Hospital.

The Post is Available in: English – 简体中文